Evidence map›Paper›PMID 40092706›Full record

ArticleJournal of Cancer2025

Mitoxantrone-liposome Sensitizes

Shiyi Yuan, Ying Zhou, Yifei Li, Zhe Chen, Wenrui Xiao, Danqing Jiang, Ping Zhang, Ying Zhang, Fengxia Bai, Jianchuan Deng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shiyi YuanDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Ying ZhouDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Yifei LiDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Zhe ChenDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Wenrui XiaoDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Danqing JiangDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Ping ZhangDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Ying ZhangDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Fengxia BaiDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Jianchuan DengDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.
Shifeng LouDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Medical University, Chongqing 400000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FMS-like tyrosine kinase 3 (

Indexed as

acute myloid leukemia (AML)cell cyclecombination therapyFLT3-ITDgilteritinibmitoxantrone-liposome

Identifiers

PMID40092706
PMCPMC11905413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.